인플루엔자 치료제 세계 시장은 2024년에 9억 5,492만 달러로 평가되고 예측 기간 동안 13억 9,222만 달러에 달할 것으로 예상되며, 2030년까지 연평균 6.46%의 CAGR을 기록할 것으로 예상됩니다.
인플루엔자는 흔한 바이러스 감염으로, 신중하고 신속하게 치료하지 않으면 사망에 이를 수도 있습니다. 코, 목, 폐를 심하게 침범하는 전염성 호흡기질환입니다. 인플루엔자 바이러스에 의한 독감을 예방하는 가장 좋은 방법은 매년 예방접종을 받는 것입니다. 콧물, 피로감, 근육통, 두통, 발열, 코막힘은 가장 전형적인 독감 증상입니다. 시장 성장을 촉진하는 주요 요인은 독감 발병률 및 유병률 증가, 세계 의료 지출 증가, 공중 보건에 대한 인식과 관심 증가로 예측 기간 동안 시장 성장을 지원할 것으로 예상됩니다.
| 시장 개요 | |
|---|---|
| 예측 기간 | 2026-2030년 |
| 시장 규모 : 2024년 | 9억 5,492만 달러 |
| 시장 규모 : 2030년 | 13억 9,222만 달러 |
| CAGR : 2025-2030년 | 6.46% |
| 급성장 부문 | 오셀타미비르 |
| 최대 시장 | 북미 |
또한, 독감 유행의 증가는 독감 치료제 시장의 성장에 기여할 수 있는 몇 가지 의미를 가지고 있습니다. 독감 환자 수가 증가함에 따라 증상 완화 및 중증도 감소를 위한 약물에 대한 수요가 증가할 것으로 예상됩니다. 이러한 수요 증가는 제약회사들이 새롭고 효과적인 독감 치료제를 개발 및 판매할 수 있는 동력이 될 것입니다. 2022년 1월 24일부터 2월 6일까지 세계보건기구(WHO)의 조사에 따르면, 약 1만 2,368명이 인플루엔자 바이러스 양성 판정을 받았습니다. 그 중 171명(6.4%)은 인플루엔자 A(H1N1), 2,483명(93.6%)은 인플루엔자 A(H3N2)에 감염된 것으로 나타났습니다. 또한, 신약 발견을 위한 R&D 투자 증가는 예측 기간 동안 시장에 유리한 기회를 창출할 것으로 예상됩니다. 그러나 시장 개척을 위한 높은 비용과 항바이러스 치료의 부작용은 2023-2030년 예측 기간 동안 시장 성장을 저해하는 요인으로 작용할 것으로 예상됩니다.
동물 질병 발생
항바이러스 저항성
만능 독감 백신
Global Influenza Drugs Market was valued at USD 954.92 Million in 2024 and is expected to reach USD 1392.22 Million in the forecast period with a CAGR of 6.46% through 2030. Influenza is a common viral infection that, if not carefully and rapidly treated, can be deadly. It affects the nose, throat, and lungs badly and is an infectious respiratory infection. The best way to prevent the flu, which is brought on by influenza viruses, is to be vaccinated annually. Runny nose, exhaustion, aches in the muscles, headaches, fever, and congestion are the most typical influenza symptoms. The key factors driving the market growth is increasing incidence and prevalence of influenza, rising healthcare expenditure worldwide, and increasing awareness and concern for public health that anticipated to support the market growth during forecast period.
| Market Overview | |
|---|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 954.92 Million |
| Market Size 2030 | USD 1392.22 Million |
| CAGR 2025-2030 | 6.46% |
| Fastest Growing Segment | Oseltamivir |
| Largest Market | North America |
Moreover, the increasing prevalence of influenza can have several implications that may contribute to the growth of the Influenza Drugs Market. As the number of influenza cases rises, there anticipated to be an increased demand for medications to alleviate symptoms and reduce the severity of the illness. This increased demand can drive pharmaceutical companies to develop and market new and more effective influenza drugs. According to a World Health Organisation study performed from January 24 to February 6, 2022, around 12,368 persons tested positive with influenza viruses. Of them, 8,423 (68.1%) were diagnosed with influenza A and 3,945 (31.9%) with influenza B. Furthermore, 171 (6.4%) were infected with influenza A (H1N1), whereas 2,483 (93.6%) were infected with influenza A (H3N2). Additionally, rise in R&D investments for discovery of new drugs is anticipated to create the lucrative opportunity for the market during forecast period. However, the high cost of drug development, and side effects associated with antiviral therapy stifles market growth throughout the forecast period of 2023-2030.
Key Market Drivers
Animal Disease Outbreaks
Antiviral demand is a significant driver in the Influenza Drugs Market, underscoring the critical role of these medications in preventing and treating influenza. Influenza, commonly known as the flu, is a highly contagious respiratory illness caused by influenza viruses, posing a substantial public health threat. Antiviral drugs, such as oseltamivir (Tamiflu) and zanamivir (Relenza), are essential in influenza treatment, functioning by inhibiting viral replication within the body. When administered promptly after symptom onset, these medications can reduce the severity and duration of influenza symptoms.
Beyond symptom alleviation, antivirals play a crucial role in preventing severe complications, especially among high-risk populations like the elderly, young children, and individuals with underlying health conditions. These drugs can significantly lower the risk of hospitalization and death. For instance, during the 2023-2024 influenza season, the Centers for Disease Control and Prevention (CDC) estimated at least 29 million illnesses, 370,000 hospitalizations, and 16,000 deaths due to influenza in the United States. Early antiviral treatment has been shown to reduce the risk of severe outcomes, including death, in hospitalized patients.
In the event of an influenza pandemic, antiviral drugs become a frontline defense. Stockpiling these medications is a crucial component of pandemic preparedness strategies, as they help mitigate virus spread and reduce the burden on healthcare systems. The World Health Organization (WHO) emphasizes the importance of maintaining antiviral stockpiles for both prophylaxis and treatment during influenza pandemics.
The demand for antiviral drugs is global, as influenza is a ubiquitous and seasonally recurrent illness affecting populations worldwide. This consistent demand ensures a stable market for influenza antivirals. Pharmaceutical companies continue to invest in research and development to enhance the effectiveness of existing antiviral drugs and to develop new agents with improved properties, further driving market growth. Government health agencies often provide guidelines and recommendations for antiviral use during influenza outbreaks, contributing to increased demand and usage.
In conclusion, antiviral demand is a pivotal driver in the Influenza Drugs Market due to the essential role these medications play in treating influenza, preventing complications, and preparing for potential pandemics. The continued focus on antiviral development and their widespread use in healthcare systems worldwide ensure that this segment remains a cornerstone of influenza management and public health initiatives.
Key Market Challenges
Antiviral Resistance
Antiviral resistance presents a significant challenge for the Influenza Drugs Market. Influenza viruses have a remarkable ability to mutate rapidly, which can lead to the emergence of strains that are less susceptible to antiviral medications. This phenomenon, known as antiviral resistance, can compromise the effectiveness of commonly used drugs like oseltamivir (Tamiflu) and zanamivir (Relenza). Antiviral resistance can render these medications less effective in treating influenza, diminishing their role in managing the disease. Patients may experience prolonged illness and an increased risk of complications, undermining the value of antiviral treatment. The development and spread of antiviral-resistant strains raise public health concerns. These strains can potentially lead to more severe influenza outbreaks and increased hospitalizations, placing additional burdens on healthcare systems. Antiviral resistance can complicate pandemic preparedness efforts. Stockpiling antiviral drugs in preparation for a potential influenza pandemic may be less effective if the circulating strain becomes resistant, necessitating the development of alternative treatment strategies.
Addressing antiviral resistance requires ongoing research and development efforts to develop new antiviral agents that are effective against resistant strains. This can be resource-intensive for pharmaceutical companies. Continuous surveillance and monitoring of influenza strains are essential to detect and respond to antiviral resistance promptly. This requires coordinated efforts between healthcare agencies and research institutions. In conclusion, antiviral resistance poses a multifaceted challenge for the Influenza Drugs Market. It not only impacts the efficacy of current treatments but also necessitates ongoing research, surveillance, and preparedness to address emerging resistant strains. Mitigating this challenge is crucial to ensure that antiviral drugs remain effective tools in managing influenza and safeguarding public health.
Key Market Trends
Universal Influenza Vaccines
Universal influenza vaccines are emerging as a prominent trend in the Influenza Drugs Market, representing a transformative shift in the approach to influenza prevention and treatment. These vaccines are designed to provide broad and long-lasting protection against multiple strains of influenza viruses, transcending the need for annual vaccine updates that specifically target predicted strains. Several factors are driving the trend of universal influenza vaccines:
The influenza virus is notorious for its ability to mutate and generate new strains. Universal vaccines aim to overcome this challenge by targeting conserved regions of the virus that are less prone to mutation, providing immunity against a broader spectrum of influenza strains. Universal vaccines have the potential to greatly reduce the strain mismatch issue that often occurs with seasonal vaccines. By offering protection against a wider range of strains, they mitigate the impact of unexpected influenza outbreaks and improve overall vaccine efficacy. Universal vaccines can play a crucial role in pandemic preparedness. In the event of a novel influenza strain with pandemic potential, these vaccines offer a more comprehensive defense, as they are not dependent on accurate strain prediction.
The shift away from annual vaccinations to less frequent universal vaccines can improve vaccine compliance and convenience for individuals and healthcare systems, reducing the burden of annual vaccination campaigns. The development of universal influenza vaccines requires extensive research and collaboration among scientists and pharmaceutical companies. This trend fuels innovation in the field and stimulates investments in advanced vaccine technologies.
In this report, the Global Influenza Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Influenza Drugs Market.
Global Influenza Drugs market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: